Literature DB >> 6681708

Haemodynamic and metabolic effects of dazoxiben at rest and during atrial pacing.

P S Kiff, G Bergman, L Atkinson, D E Jewitt, J Westwick, V V Kakkar.   

Abstract

1 Thromboxane B2 (TXB2) levels were measured in three sites (coronary sinus, pulmonary artery, and femoral artery) at rest and during atrial pacing in 11 patients with stable angina pectoris. 2 There was a highly significant increase in arterial TXB2 on pacing (by up to 820 pg/ml) but there was no change in the thromboxane levels at the other two sites. 3 Dazoxiben 200 mg orally abolished the increase in arterial TXB2, but had no effect on systemic, pulmonary or coronary haemodynamics, no effect on myocardial metabolism and a variable effect on atrial pacing time to angina.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6681708      PMCID: PMC1427677          DOI: 10.1111/j.1365-2125.1983.tb02112.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Platelet aggregates in peripheral and coronary-sinus blood in patients with spontaneous coronary-artery spasm.

Authors:  R M Robertson; D Robertson; G C Friesinger; S Timmons; J Hawiger
Journal:  Lancet       Date:  1980-10-18       Impact factor: 79.321

2.  Thromboxane release during pacing-induced angina pectoris: possible vasoconstrictor influence on the coronary vasculature.

Authors:  R I Lewy; L Wiener; P Walinsky; A M Lefer; M J Silver; J B Smith
Journal:  Circulation       Date:  1980-06       Impact factor: 29.690

3.  Elevation of thromboxane B2 levels in patients with classic and variant angina Pectoris.

Authors:  M Tada; T Kuzuya; M Inoue; K Kodama; M Mishima; M Yamada; M Inui; H Abe
Journal:  Circulation       Date:  1981-12       Impact factor: 29.690

4.  Beneficial effect of enhanced myocardial carbohydrate utilisation after oxfenicine (L-hydroxyphenylglycine) in angina pectoris.

Authors:  G Bergman; L Atkinson; J Metcalfe; N Jackson; D E Jewitt
Journal:  Eur Heart J       Date:  1980-08       Impact factor: 29.983

5.  Prostacyclin: haemodynamic and metabolic effects in patients with coronary artery disease.

Authors:  G Bergman; K Daly; L Atkinson; M Rothman; P J Richardson; G Jackson; D E Jewitt
Journal:  Lancet       Date:  1981-03-14       Impact factor: 79.321

6.  Coronary vasoconstrictor effect of indomethacin in patients with coronary-artery disease.

Authors:  P L Friedman; E J Brown; S Gunther; R W Alexander; W H Barry; G H Mudge; W Grossman
Journal:  N Engl J Med       Date:  1981-11-12       Impact factor: 91.245

7.  Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials.

Authors:  R M Robertson; D Robertson; L J Roberts; R L Maas; G A FitzGerald; G C Friesinger; J A Oates
Journal:  N Engl J Med       Date:  1981-04-23       Impact factor: 91.245

8.  Circulating platelet products in unstable angina pectoris.

Authors:  M Sobel; E W Salzman; G C Davies; R I Handin; J Sweeney; J Ploetz; G Kurland
Journal:  Circulation       Date:  1981-02       Impact factor: 29.690

9.  Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease.

Authors:  P D Hirsh; L D Hillis; W B Campbell; B G Firth; J T Willerson
Journal:  N Engl J Med       Date:  1981-03-19       Impact factor: 91.245

  9 in total
  1 in total

1.  Effect of the specific thromboxane receptor blocking drug AH23848 in patients with angina pectoris.

Authors:  D P De Bono; P Lumley; M Been; R Keery; S E Ince; D F Woodings
Journal:  Br Heart J       Date:  1986-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.